Future Perspectives on HER2 ADCs in Gynecological Cancer
February 8th 2024Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.
Read More
Expert Insights on HER2 Testing in Gynecological Cancers
February 8th 2024Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.
Read More
HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors
January 11th 2024Martin Dietrich, MD, PhD, reflects on the lessons and insights gleaned from HER2 in breast cancer, examining their influence on the development of treatment approaches utilizing HER2-targeted therapies in other solid tumors.
Read More
Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight
December 27th 2023Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.
Read More
UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations
December 27th 2023Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
Read More
Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC
December 20th 2023Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Read More